AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $46.1250.

Several analysts have recently issued reports on ANAB shares. JPMorgan Chase & Co. increased their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Wedbush increased their price objective on AnaptysBio from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. UBS Group reissued a “neutral” rating and issued a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. HC Wainwright raised AnaptysBio from a “neutral” rating to a “buy” rating and increased their target price for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. Finally, Guggenheim reissued a “buy” rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the business’s stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the completion of the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently modified their holdings of the company. US Bancorp DE boosted its holdings in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 979 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,858 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,531 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its holdings in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 936 shares during the last quarter.

AnaptysBio Trading Down 0.6%

Shares of NASDAQ ANAB opened at $20.02 on Tuesday. The stock has a market cap of $560.50 million, a P/E ratio of -4.47 and a beta of -0.20. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $40.70. The business’s fifty day simple moving average is $23.92 and its 200-day simple moving average is $20.61.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The business had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. On average, equities analysts forecast that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.